
Adrenocortical Carcinoma- Pipeline Insight, 2024
Description
Adrenocortical Carcinoma- Pipeline Insight, 2024
DelveInsight’s, “Adrenocortical Carcinoma- Pipeline Insight, 2024” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Adrenocortical Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Adrenocortical Carcinoma: Overview
Adrenocortical carcinoma is cancer that forms in the outer layer (cortex) of the adrenal glands. There are two adrenal glands, one located at the top of each kidney. The adrenal cortex makes hormones — including cortisol, testosterone, aldosterone and estrogen. These hormones control male and female traits and body functions such as blood pressure and response to stress. An adrenocortical carcinoma (ACC) is a cancerous adrenal tumor that forms in the adrenal cortex. There are two types of ACC:
- Functioning ACC tumor: A functioning ACC tumor causes your adrenal gland to make more hormones than it normally should.
- Nonfunctioning ACC tumor: This type of tumor doesn’t affect hormone production.
- A functioning ACC can cause symptoms related to the overproduction of hormones.
- If the adrenal tumor grows large enough, it may press on nearby organs. This pressure can cause pain or other symptoms.
Weight gain in the face, neck and trunk (but not arms and legs).
The healthcare provider will start with a physical exam to diagnose afrenocortical carcinoma. If symptoms point to adrenal cancer, the following diagnostic tests must be conducted:
- Imaging tests, such as MRI, CT scan or PET scan to look for tumors.
- Blood and urine tests to check hormone levels.
- A dexamethasone suppression test to measure cortisol levels.
- Biopsy to determine if a tumor is cancerous.
""Adrenocortical Carcinoma- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Adrenocortical Carcinoma pipeline landscape is provided which includes the disease overview and Adrenocortical Carcinoma treatment guidelines. The assessment part of the report embraces, in depth Adrenocortical Carcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Adrenocortical Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Adrenocortical Carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve Adrenocortical Carcinoma.
This segment of the Adrenocortical Carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Adrenocortical Carcinoma Emerging Drugs
- Relacorilant: Corcept Therapeutics
- Ipilimumab: Bristol-Myers Squibb
Further product details are provided in the report……..
Adrenocortical Carcinoma: Therapeutic Assessment
This segment of the report provides insights about the different Adrenocortical Carcinoma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Adrenocortical Carcinoma
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
- Molecule Type
- Monoclonal antibody
- Small molecule
- Peptide
- Product Type
Adrenocortical Carcinoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Adrenocortical Carcinoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Adrenocortical Carcinoma drugs.
Adrenocortical Carcinoma Report Insights
- Adrenocortical Carcinoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Adrenocortical Carcinoma drugs?
- How many Adrenocortical Carcinoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Adrenocortical Carcinoma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Adrenocortical Carcinoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Adrenocortical Carcinoma and their status?
- What are the key designations that have been granted to the emerging drugs?
- Corcept Therapeutics
- Bristol-Myers Squibb
- Enterome
- Exelixis/Ipsen
- Genentech
- Relacorilant
- Ipilimumab
- EO 2401
- Cabozantinib
- Atezolizumab
Key Players
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Adrenocortical Carcinoma: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Adrenocortical Carcinoma– DelveInsight’s Analytical Perspective
- Mid Stage Products (Phase II)
- Comparative Analysis
- Ipilimumab: Bristol-Myers Squibb
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Relacorilant: Corcept Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Adrenocortical Carcinoma Key Companies
- Adrenocortical Carcinoma Key Products
- Adrenocortical Carcinoma- Unmet Needs
- Adrenocortical Carcinoma- Market Drivers and Barriers
- Adrenocortical Carcinoma- Future Perspectives and Conclusion
- Adrenocortical Carcinoma Analyst Views
- Adrenocortical Carcinoma Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.